Viral Conjunctivitis Drugs in Development Pipeline Guide 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com
DUBLIN, May 19, 2022--(BUSINESS WIRE)--The "Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
The pipeline guide provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Viral Conjunctivitis pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 6 and 1 respectively.
The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Report Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)
Key Topics Covered:
Viral Conjunctivitis - Overview
Viral Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Viral Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Viral Conjunctivitis - Companies Involved in Therapeutics Development
Invirsa Inc
IVIEW Therapeutics Inc
Kiora Pharmaceuticals Inc
Microbiotix Inc
NanoViricides Inc
Okogen Inc
Plex Pharmaceuticals Inc
Starpharma Holdings Ltd
TGV-Inhalonix Inc
Viral Conjunctivitis - Drug Profiles
astodrimer - Drug Profile
EKCCide-I - Drug Profile
filociclovir - Drug Profile
INV-102 - Drug Profile
KIO-101 - Drug Profile
Mul-1867 - Drug Profile
OKG-0502 - Drug Profile
povidone iodine ER - Drug Profile
ranpirnase - Drug Profile
Viral Conjunctivitis - Dormant Projects
Viral Conjunctivitis - Discontinued Products
Viral Conjunctivitis - Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/r/ihtz8b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005532/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900